文献速递临床试验与 GCP流行病学与生物统计基础与转化研究

病理完全缓解作为早期乳腺癌新辅助随机临床试验替代终点的评估:系统综述与荟萃分析

Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis.
PubMed 文献 · BMJ · 2021-12-21

该系统综述与荟萃分析纳入54项随机临床试验共32611例早期乳腺癌患者,评估新辅助治疗中病理完全缓解(pCR)与无病生存期(DFS)和总生存期(OS)的试验水平关联。结果显示pCR与DFS(R²=0.14,95%CI 0.00-0.29)及OS(R²=0.08,95%CI 0.00-0.22)关联均弱,pCR的替代阈值效应在DFS为5.19,在OS无法估计。结论认为pCR在监管性新辅助试验中缺乏替代性,不应作为主要终点。

要点

  • pCR与DFS的试验水平关联弱(R²=0.14,95%CI 0.00-0.29)。
  • pCR与OS的试验水平关联弱(R²=0.08,95%CI 0.00-0.22)。
  • pCR的替代阈值效应在DFS为5.19,在OS无法估计。

核心结论

  • 在试验水平上,病理完全缓解(pCR)对无病生存期(DFS)和总生存期(OS)均缺乏替代性。
  • 研究结果提示,pCR不应在早期乳腺癌的监管性新辅助试验中用作主要终点。

研究设计与样本

  • 研究设计为系统综述与荟萃分析,检索Medline、Embase和Scopus数据库至2020年12月1日。
  • 纳入标准为测试新辅助化疗(单用或联合其他治疗,包括抗人表皮生长因子受体2(anti-HER2)药物、靶向治疗、抗血管药物、双膦酸盐和免疫检查点抑制剂)的随机临床试验。
  • 共纳入54项随机临床试验,总计32611例患者。
  • 采用加权回归分析对数转换后的治疗效应估计值(DFS和OS的风险比及pCR的相对风险),以决定系数(R²)量化关联。

主要发现

  • pCR的对数相对风险与DFS的对数风险比之间关联弱(R²=0.14,95%CI 0.00-0.29)。
  • pCR的对数相对风险与OS的对数风险比之间关联弱(R²=0.08,95%CI 0.00-0.22)。
  • 在所有评估的亚组中结果相似,与pCR定义、实验组治疗类型及疾病生物学特征无关。
  • pCR的替代阈值效应在DFS为5.19,在OS无法估计。
  • 三项敏感性分析(排除小样本试验(入组<200例患者)、排除中位随访时间短(<24个月)的试验、以两组pCR率绝对差替代pCR相对风险)均证实结果一致。

关键数值与推荐

  • pCR与DFS的试验水平关联:R²=0.14(95%CI 0.00-0.29)。
  • pCR与OS的试验水平关联:R²=0.08(95%CI 0.00-0.22)。
  • pCR的替代阈值效应在DFS为5.19,在OS无法估计。

临床怎么用

  • 原文结论提示,pCR不应在早期乳腺癌的监管性新辅助试验中用作主要终点。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate pathological complete response as a surrogate endpoint for disease-free survival and overall survival in regulatory neoadjuvant trials of early stage breast cancer. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Medline, Embase, and Scopus to 1 December 2020. ELIGIBILITY CRITERIA FOR STUDY SELECTION: Randomised clinical trials that tested neoadjuvant chemotherapy given alone or combined with other treatments, including anti-human epidermal growth factor 2 (anti-HER2) drugs, targeted treatments, antivascular agents, bisphosphonates, and immune checkpoint inhibitors. DATA EXTRACTION AND SYNTHESIS: Trial level associations between the surrogate endpoint pathological complete response and disease-free survival and overall survival. METHODS: A weighted regression analysis was performed on log transformed treatment effect estimates (hazard ratio for disease-free survival and overall survival and relative risk for pathological complete response), and the coefficient of determination (R2) was used to quantify the association. The secondary objective was to explore heterogeneity of results in preplanned subgroups analysis, stratifying trials according treatment type in the experimental arm, definition used for pathological complete response (breast and lymph nodes v breast only), and biological features of the disease (HER2 positive or triple negative breast cancer). The surrogate threshold effect was also evaluated, indicating the minimum value of the relative risk for pathological complete response necessary to confidently predict a non-null effect on hazard ratio for disease-free survival or overall survival. RESULTS: 54 randomised clinical trials comprising a total of 32 611 patients were included in the analysis. A weak association was observed between the log(relative risk) for pathological complete response and log(hazard ratio) for both disease-free survival (R2=0.14, 95% confidence interval 0.00 to 0.29) and overall survival (R2 =0.08, 0.00 to 0.22). Similar results were found across all subgroups evaluated, independently of the definition used for pathological complete response, treatment type in the experimental arm, and biological features of the disease. The surrogate threshold effect was 5.19 for disease-free survival but was not estimable for overall survival. Consistent results were confirmed in three sensitivity analyses: excluding small trials (<200 patients enrolled), excluding trials with short median follow-up (<24 months), and replacing the relative risk for pathological complete response with the absolute difference of pathological complete response rates between treatment arms. CONCLUSION: A lack of surrogacy of pathological complete response was identified at trial level for both disease-free survival and overall survival. The findings suggest that pathological complete response should not be used as primary endpoint in regulatory neoadjuvant trials of early stage breast cancer.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Conforti F, Pala L, Sala I, et al. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ. 2021. PMID: 34933868. doi:10.1136/bmj-2021-066381

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。